Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Market Cap	62.10B
Revenue (ttm)	6.98B
Net Income (ttm)	359.76M
Shares Out	n/a
EPS (ttm)	0.42
PE Ratio	172.62
Forward PE	48.39
Dividend	0.32 (0.62%)
Ex-Dividend Date	Jun 12, 2025

Volume	2,871,700
Average Volume	4,627,572
Open	56.75
Previous Close	55.65
Day's Range	55.70 - 59.70
52-Week Range	22.30 - 60.60
Beta	0.83
RSI	62.08
Earnings Date	Aug 29, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 10,185
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3347

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY